The stock of Angiodynamic Inc (NASDAQ: ANGO) has increased by 12.89 when compared to last closing price of 9.70. Despite this, the company has experienced a 12.77% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-30 that Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Is It Worth Investing in Angiodynamic Inc (NASDAQ: ANGO) Right Now?
The stock has a 36-month beta value of 0.62. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANGO is 38.73M, and at present, short sellers hold a 4.77% of that float. On June 04, 2025, the average trading volume of ANGO was 509.37K shares.
ANGO’s Market Performance
The stock of Angiodynamic Inc (ANGO) has seen a 12.77% increase in the past week, with a 17.87% rise in the past month, and a 16.37% gain in the past quarter. The volatility ratio for the week is 7.57%, and the volatility levels for the past 30 days are at 4.00% for ANGO. The simple moving average for the last 20 days is 14.68% for ANGO stock, with a simple moving average of 24.47% for the last 200 days.
Analysts’ Opinion of ANGO
Many brokerage firms have already submitted their reports for ANGO stocks, with Oppenheimer repeating the rating for ANGO by listing it as a “Outperform.” The predicted price for ANGO in the upcoming period, according to Oppenheimer is $12 based on the research report published on April 05, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ANGO reach a price target of $19. The rating they have provided for ANGO stocks is “Buy” according to the report published on September 25th, 2023.
Raymond James gave a rating of “Outperform” to ANGO, setting the target price at $13 in the report published on April 17th of the previous year.
ANGO Trading at 14.77% from the 50-Day Moving Average
After a stumble in the market that brought ANGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANGO starting from Nighan Warren JR, who sale 4,060 shares at the price of $12.31 back on Jan 16 ’25. After this action, Nighan Warren JR now owns 41,817 shares of Angiodynamic Inc, valued at $49,979 using the latest closing price.
Nighan Warren JR, the Officer of Angiodynamic Inc, proposed sale 4,060 shares at $12.31 during a trade that took place back on Jan 16 ’25, which means that Nighan Warren JR is holding shares at $49,979 based on the most recent closing price.
Stock Fundamentals for ANGO
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.53 for the gross margin
The net margin for Angiodynamic Inc stands at -0.15. The total capital return value is set at -0.12. Equity return is now at value -20.46, with -13.57 for asset returns.
Based on Angiodynamic Inc (ANGO), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -4.79. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -44.9.
Currently, EBITDA for the company is -14.29 million with net debt to EBITDA at 5.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.43. The receivables turnover for the company is 5.79for trailing twelve months and the total asset turnover is 0.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.21.
Conclusion
To sum up, Angiodynamic Inc (ANGO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
